Kornimate/medical-research-clean huggingface dataset:
mindreading in adults with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: this study aims to investigate the ability of reading emotions by the eyes task in adults with asd, and examine the gazing pattern and frontal activation during the task. we plan to recruit 50 adults with asd and 50 typically-developing adults. eye-tracking and frontal activation (measured by functional near-infrared spectroscopy) will be examined during the eyes task.

autism spectrum disorder (asd) is a clinical syndrome characterized by mindreading deficits, or theory of mind deficits. the reading the mind in the eyes task (abbreviated as the eyes task) was developed to assess the mindreading deficits as a hallmark of social deficits of asd. this study aims to investigate the ability of reading emotions by the eyes task in adults with asd, and examine the gazing pattern and frontal activation during the task. we plan to recruit 50 adults with asd and 50 typically-developing adults. all the participants will complete clinical measures and the eyes task. eye-tracking and frontal activation (measured by functional near-infrared spectroscopy) will be examined during the eyes task.

Eligibility criteria:
inclusion criteria: * adult aged between 20 and 50 years who had a diagnosis of asd based on dsm-5. * had a full-scale iq \> 70 on wais-iv. exclusion criteria: * a history of major mental illness (e.g., bipolar affective disorder, schizophrenia) or neurological diseases. * visual impairment and that would preclude participation.
application of 3d mr neurogram for intraparotid facial nerves evaluation

Conditions: Parotid Neoplasms

Summary: parotid neoplasm consists of a wide range of benign and malignant lesions, and parotidectomy has been the mainstay for management of these neoplasms. within the parotid gland there are branches of the intra-parotid facial nerves, which are tiny in calibre and are prone to injury to injury during operation. it has been reported in recent retrospective view that the incidence of temporary and permanent facial nerve injury were 9.2% and 5.2% respectively, the risk of which increased with old age, malignant tumour and revision surgery. traditional the incidental of facial nerve injury is reduced by intra-operative facial nerve monitoring and surgical magnification, while imaging has limited role in aiding this purpose. however with advancement in mri technique high resolution three-dimensional sequences (i.e. neurogram sequences) are available for better visualization of branches of facial nerves. the investigators would therefore aim to demonstrate additional efficacy of these techniques and also to compare with conventional 3d post-contrast anatomical imaging studies in the localization and visualization of the facial nerve branches in patients with tumour. with better pre-operative imaging, the investigators hope to reduce the chance of facial nerve injury in these patients.


Eligibility criteria:
inclusion criteria: * consecutive patients with parotid tumour diagnosed on other imaging modalities (such as ultrasonography or computed tomography), with or without cytological diagnosis from fine needle aspiration, will be recruited from the ear, nose and throat specialty clinic. exclusion criteria: * patients who are contraindicated to magnetic resonance imaging (such as due to underlying mri incompatible metallic implants) * patient who are contraindicated to mri contrast agents (such as advanced renal failure or previous severe allergic reaction) * patients who cannot cooperate for mri scanning. * patients show are unable to provide informed consent.
safety and performance of mirasol® prt treated platelet transfusion products

Conditions: Thrombocytopenia

Summary: the primary objective of the study is to measure platelet corrected count increments and the incidence of serious adverse events (sae). the primary endpoint is the platelet corrected count increment measured 1-hour post transfusion in response to the infusion of platelet concentrates treated with the mirasol prt system device (test product) versus untreated (reference product).

the objective of the study is to determine if the mirasol pathogen reduction technology (prt) system for platelets device performs safely and maintains adequate platelet performance in a clinical setting. this will be achieved by comparing the platelet corrected count increment measured 1 hour post transfusion and the incidence of serious adverse events in response to the infusion of platelet concentrates treated with the device (test product) versus untreated (reference product) in thrombocytopenic subjects requiring platelet transfusions. the performance, safety, and tolerability profile of the device will be further assessed by monitoring and comparing the incidence of discontinuations due to adverse events in relation to platelet transfusion up to 4 weeks after transfusion, including the incidence of transfusion associated infections, and the number and time between transfusions.

Eligibility criteria:
inclusion criteria: * male or female of age of 16 years or older * women of child bearing potential not pregnant * subject must have signed and dated the informed consent form * hospitalized, thrombocytopenic subjects and expected to receive at least two platelets transfusion exclusion criteria: * history of any hypersensitivity reaction to riboflavin or metabolites * history of refractoriness to platelet transfusions * positive lymphocytotoxic antibody test * active bleeding * splenomegaly * acute or chronic disseminated intravascular coagulation * history or diagnosis of immune/idiopathic thrombocytopenic purpura, thrombotic thrombocytopenia purpura, or haemolytic uremic syndrome * history or diagnosis of an autoimmune disease affecting haemostasis * history of solid organ transplants * evidence of occlusive venous disease * clinical signs of infection at the time of inclusion * pregnant or lactating females * chronic alcohol misuse * use of prohibited medications
prophylactic cranial irradiation (pci) cognitive tests in non-small cell lung cancer (nsclc) patients

Conditions: NSCLC

Summary: stage iii non-small cell lung cancer (nsclc) patients constitute a significant proportion of the lung cancer population. the prognosis of these patients has improved over the years due the introduction of combined modality treatment, including high-dose chemo-radiotherapy. the brain, however, remains one of the major sites of failure. patients with brain metastasis suffer from a variety of neurological, cognitive and emotional difficulties that are known to adversely affect the health-related quality of life. prophylactic cranial irradiation (pci) can prevent or delay the development of brain metastasis, and as such can improve neurological disease-free survival and consequently health-related quality of life. but survival is short, and toxicities are real, as pci in itself can also induce adverse effects. the cognitive adverse effects of pci are not sufficiently illuminated and documented, due to the lack of formal and systematic evaluation in patient populations expected to have short survival. also, recent attempts to reduce cognitive side effects of pci by the application of hippocampal-avoidance pci in order to prevent memory deficits have not been fully evaluated yet. before pci can be offered routinely to stage iii nsclc patients in daily practice, the costs and benefits of this therapy should be investigated properly, to allow for well-informed treatment choices.


Eligibility criteria:
inclusion criteria: * uicc stage iii a or iii b (without malignant pleural or pericardial effusion) non-small cell lung cancer * whole body pdg-pet scan before the start of therapy available: no distant metastasis. * ct or preferably mri of the brain before the start of radical therapy available; no brain metastasis. * platinum-based chemotherapy is mandatory. * radical local therapy: concurrent or sequential chemotherapy and radiotherapy with or without surgery. * radiotherapy dose without surgery to at least biological equivalent of 60 gy. * no prior cranial irradiation.sufficient proficiency in dutch language * sufficient proficiency in dutch language * mri (and not ct scan) pre-pci exclusion criteria: * none

Keywords: prophylactic cranial irradiation lung cancer
assessment of mechanisms of improved wound healing

Conditions: Burns

Summary: the purpose of this study is to find ways to improve wound healing and decrease the negative effects of trauma from burn injury.

this study involves research and the investigators hope to learn the following: how or what effect one or more anabolic ("tissue building") agents have on muscle metabolism, wound healing, and immune function after severe burn. the agents include the following: growth hormone, insulin-like growth factor-1 in combination with its binding proteins, insulin, beta-adrenergic blockers, alpha adrenergic agonist, anabolic steroids such as testosterone, oxandrolone and nandrolone, ketoconazole and its derivatives, dehydroepiandrosterone, fenofibrate, diet or the application of skin substitute.

Eligibility criteria:
inclusion criteria: * patient is between 0 and 90 years of age * patient 18 years and older consents to participate in study protocol. if patient is not able to consent, consent will be obtained from closest family member or legal guardian. parental permission will be obtained for patients less than 18 years of age. assent will be obtained from children 7-17 years of age if child is physically/mentally able to do so. * greater than 30% tbsa burn requiring at least 1 operation with donor sites for skin grafting exclusion criteria: * known history of aids, aids-related complex, human immunodeficiency virus * history of cancer within 5 years * tuberculosis, arthritis, cirrhosis, hyperlipidemia, bone or endocrine diseases, autoimmune diseases * chronic glucocorticoid or non-steroidal anti-inflammatory drug therapy

Keywords: burns
efficacy, safety and tolerability of repeated dosis of intravitreous bevacizumab in uveitic macular oedema

Conditions: Uveitis

Summary: the purpose of this study is to determine whether intravitreous bevacizumab or intravitreous triamcinolone acetonide are effective and safe in the treatment of uveitic macular oedema


Eligibility criteria:
inclusion criteria: * adult patients with uveitis or retinal vasculitis with unilateral or bilateral macular oedema * with macular thickness \> 250 micra using oct * visual acuity at least 20/200 * with stable treatment with oral prednisone at least during 3 months, either oral ciclosporin or other immunomodulator to treat intraocular inflammatory disease * patient that can follow study's requirements * patient who consents to participate exclusion criteria: * presence of corneal or crystalline opacity preventing observation of fundus of eye * patients requiring ocular surgery in next 3 months * one-eyed * pregnancy and child breastfeeding * previous history of glaucoma * on treatment woth an experimental ocular drug * previous thromboembolism or receiving oral anticoagulant treatment * vitrectomy * patients with proved tractional macular pathology associated to macular oedema
the clinical and biochemical effect of therapeutic massage on fatigue and insomnia in women with breast cancer receiving radiation therapy

Conditions: Breast Cancer; Fatigue; Insomnia

Summary: a majority of women with breast cancer receive radiation therapy, and many of them experience the debilitating side effects of fatigue and insomnia. there is a need for an effective treatment that could ameliorate these symptoms and improve quality of life in the radiation therapy population. the primary purpose of the proposed research is to study the impact of massage therapy as a tool for the management of fatigue and insomnia experienced by women diagnosed with breast cancer and receiving radiation therapy. the secondary purpose is to explain, at the biochemical level, the effect of therapeutic massage on the level of fatigue and insomnia in radiation therapy patients. prior studies have shown an association between fatigue and insomnia in the breast cancer patient following radiation therapy and the presence of inflammation as evidenced by increased proinflammatory cytokine production. the investigators hypothesize that therapeutic massage will ameliorate the symptoms of fatigue and insomnia associated with radiation therapy, and will be associated with a reduction in the plasma levels of interleukin-6 (il-6),soluble il-6 receptor (sil-6r/cd126), and c-reactive protein (crp). this reduction in proinflammatory biomarkers will be due to the activation of the cholinergic anti-inflammatory pathway via the activation of the vagus nerve.


Eligibility criteria:
inclusion criteria: * female patients and * \> or = 18 years of age and * diagnosed with breast cancer and * undergoing radiation therapy and * willing to follow protocol requirements exclusion criteria: * stage iv disease or * presence of an underlying disease that is anticipated to be fatal w/in 6 mo * long term steroid medications in the past year or * plans to move out of study region within six months or * receiving regular body work over the past six months

Keywords: therapeutic massage massage inflammation fatigue insomnia radiation therapy breast cancer breast cancer patients receiving radiation therapy
investigating severe acute respiratory syndrome (sars)

Conditions: SARS Virus

Summary: severe acute respiratory syndrome (sars) is a newly recognized illness that can be fatal. the purpose of this study is to better understand sars by collecting samples of blood and other body fluids of people who have been exposed to sars or who are suspected to have the illness. up to 300 volunteers aged 18 years or older will be enrolled in this study. participants will donate blood samples and, if appropriate, samples of fluid from the lungs, nose, or throat. researchers will test these samples for proteins that control or mediate inflammatory or immune responses. the patterns of these proteins will reveal how sars affects the body and the efforts the body makes to fight off the infection.

severe acute respiratory syndrome (sars) is a newly recognized illness associated with substantial mobidity and mortality. patients develop fever followed by rapidly progressive and even fatal respiratory disease. sars is associated with infection with a novel coronavirus. the evaluation of the inflammatory responses evoked by sars may yield information regarding its pathogenesis and help with patient management. this protocol, then, merely aims to study disease pathogenesis and natural history, by studying samples and data that are collected by outside physicians or physicians at the clinical center and sent for evaluation of the inflammatory response.

Eligibility criteria:
* inclusion criteria - cases: patients fulfilling the cdc case definition or who definition for suspected or probable sars. newly identified patients found to have recovered from sars can also be enrolled. exclusion criteria - cases: patients diagnosed with alternative illnesses as the cause of the symptoms. inclusion criteria - healthy volunteers: for the purpose of this study, a healthy volunteer is defined as a healthy male or female, age 18 and above. volunteers will be excluded if they have a pre-existing or concurrent serious chronic medical or psychiatric illness. chronic medication use will be evaluated on a case-by-case basis. they will also be excluded if they have received an investigational drug in the past 3 months.

Keywords: inflammation coronavirus immunity interferon cytokine severe acute respiratory syndrome sars healthy volunteer hv
the association of g9a protein and clinical outcome of patients with vulvar cancer

Conditions: Vulvar Cancer, G9a Protein

Summary: to assess the g9a expression in vulvar cancer

vulvar cancer can be treated with surgery, radiotherapy or chemoradiotherapy. recurrence of vulvar cancer generally can be detected by imaging study. currently, there is a paucity of sensitive marker to detect the recurrence of vulvar cancer. g9a is a recently identified protein with histone lysine methyltransferase activity. the role of histone methyltransferases in promoting tumorigenesis and progression of human cancers has been noted in some cancers, such as ovarian cancer, endometrial cancer and cervical cancer. the role of g9a protein in vulvar cancer remains obscure. all female patients with vulvar cancer or vulvar intraepithelial neoplasm ii /iii who underwent surgery at far eastern memorial hospital from january 2003 will be included. all patients' clinical characteristerics including age, stage, pathologic finding, and follow-up data will be recorded from chart review. the archived specimens will be used for immunohistochemical staining of g9a protein. tumor size, local invasion, lymph node metastasis, and final disease stage will be determined. correlation will be performed between g9a and clinical outcome of vulvar cancer.

Eligibility criteria:
inclusion criteria: * all female patients with vulvar cancer or vulvar intraepithelial neoplasm ii /iii who underwent surgery at far eastern memorial hospital from january 2003 were included. exclusion criteria: * n/a
immunogenicity, safety and lot to lot consistency of novartis meningococcal b recombinant vaccine when administered with routine infant vaccinations to healthy infants

Conditions: Serogroup B Meningococcal Meningitis

Summary: the proposed study was aimed to assess the immunogenicity, safety, tolerability and lot to lot consistency of 3 lots of novartis meningococcal b vaccine when given concomitantly with routine infant vaccines.


Eligibility criteria:
inclusion criteria: * healthy 2-month old infants (55-89 days, inclusive) exclusion criteria: * prior vaccination with routine infant vaccines (diphtheria, tetanus, pertussis, polio, haemophilus influenzae type b (hib), and pneumococcal antigens) * previous ascertained or suspected disease caused by n. meningitidis * history of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component; * any serious chronic or progressive disease * known or suspected impairment or alteration of the immune system

Keywords: infant meningococcal disease prevention vaccination
sequence variations of genes in the estrogen pathway and perinatal depression

Conditions: Postnatal Depression; Genetic Predisposition

Summary: to elucidate the disease pathway of perinatal depression by identifying genetic variants which could play a role in predisposing to the condition and/or lead to better understanding of the pathogenesis of the condition. this is achieved by investigating for associations between oestrogen receptor genetic variants and perinatal depression.

perinatal (antenatal and postnatal) depression is a common complication of childbearing, affecting 10 to 20% of mothers. in general, women are exposed to fluctuations in estrogen level during childbearing years, especially during pregnancy and following childbirth. for a subgroup of women with genetic predisposition rendering them more sensitive to such changes, pregnancy or childbirth can act as a trigger for the onset of perinatal depression. a case control study will be conducted to evaluate the association of variants in estrogen receptor and related genes with the disorder in our population. women attending antenatal and postnatal clinics will be screened with the edinburgh postnatal depression scale and cases will be identified. dna from controls who are well throughout the antenatal and postpartum period and cases meeting dsm iv criteria for depressive disorder will be genotyped for various genetic variants. the distribution of single nucleotide polymorphisms and haplotypes and non-genetic risk factors will be compared between cases and controls and within the case group. the risk factors for postnatal depression in relation to peripartum factors such as demographic, obstetric, anaesthetic and pain outcomes will be investigated. as perinatal depression is known to contribute to inadequate self-care and poor compliance with prenatal care, early diagnosis and treatment interventions are critical for the health and well-being of both mother and infant. in the short term, identified genetic markers that increase vulnerability to puerperal triggering of depression can be an additional screening tool to identify at-risk expectant mothers for early management during a very critical period for mother, infant, and family. in the long run, it may lead to identification of new pathways or treatment targets for this common but under-studied disorder.

Eligibility criteria:
inclusion criteria: * anthropometric profile: age 21-35 years; chinese race; chinese ancestry for all 4 grandparents * natural conception (not artificially assisted) * cases: depressive episode during antenatal period or \< 6 months postnatal at time of recruitment; patients with past diagnosis of depression must have been well for 3 months before pregnancy * controls: well during antenatal period or \> 6 months postnatal at time of recruitment; no family history of depression or affective disorders exclusion criteria: * other psychiatric disorders (non-mood disorders) namely schizophrenia and substance dependence * previously diagnosed neurological disorders
dw evaluation of lotrafilcon b lenses in a modified design

Conditions: Myopia

Summary: the purpose of this study is to demonstrate that lotrafilcon b air optix® aqua sphere modified design lenses are noninferior to lotrafilcon b air optix® aqua in overall lens fit by comparing the percent of subjects satisfying the "no re-fit" criteria in each treatment group.


Eligibility criteria:
inclusion criteria: * must sign an informed consent document; * myopic, wear air optix® aqua lenses in the range of -1.00 to -5.00 diopters (d) in both eyes, and willing to comply with the wearing schedule; * manifest cylinder less than or equal to 0.75 d; * able to achieve best corrected visual acuity (bcva) of 20/25 (snellen) or better in each eye at distance; * able to achieve distance visual acuity of at least 20/40 in each eye with habitual and study lenses; * wearing spherical air optix® aqua lenses in both eyes for at least 3 months (at least 8 hours per day, at least 5 days per week), wearing the habitual lenses for a minimum of 4 hours prior to the baseline study visit, and achieving an acceptable or optimal fit at baseline visit with habitual lenses in both eyes; * other protocol-defined criteria may apply. exclusion criteria: * current soft contact lens wearer who regularly sleeps in lenses (1 or more nights per week); * any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment; * any use of systemic or ocular medications for which contact lens wear could be contraindicated including any use of topical ocular medications that would require instillation during contact lens wear; * history of herpetic keratitis; * history of corneal or refractive surgery or irregular cornea; * a pathologically dry eye that precludes contact lens wear; * monocular (only one eye with functional vision); * monovision correction; * history of intolerance or hypersensitivity to any component of the test articles or associated materials; * concurrent participation in a contact lens or contact lens care product clinical trial or within the previous 30 days; * eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment; * any ocular or systemic medical condition that may, in the opinion of the investigator, preclude safe administration of the study lenses or affect the results of this study; * other protocol-defined exclusion criteria may apply.

Keywords: lens fit contact lenses myopia